Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Altimmune, Inc. - Common Stock
(NQ:
ALT
)
4.070
+0.070 (+1.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altimmune, Inc. - Common Stock
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
19
20
Next >
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
March 15, 2024
Viking Therapeutics just might be an attractive acquisition target for Pfizer.
Via
The Motley Fool
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
March 03, 2024
WHY: NEW YORK, NY - (NewMediaWire) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,...
Via
NewMediaWire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
March 03, 2024
WHY: NEW YORK, NY - (NewMediaWire) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,...
Via
TheNewswire.com
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
March 01, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today
February 28, 2024
Via
Benzinga
(ALT) - Analyzing Altimmune's Short Interest
February 14, 2024
Via
Benzinga
How Is The Market Feeling About Altimmune?
January 26, 2024
Via
Benzinga
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
March 01, 2024
WHY: NEW YORK, NY - (NewMediaWire) - March 01, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,...
Via
TheNewswire.com
Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review
March 01, 2024
The Nasdaq is on the cusp of setting a record high.
Via
Investor's Business Daily
Topics
Economy
ALT LOSS ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
February 27, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ALT LOSS ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
February 27, 2024
WHY: NEW YORK, NY - (NewMediaWire) - February 27, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,...
Via
TheNewswire.com
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via
Benzinga
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 26, 2024
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.
Via
Benzinga
Stocks Start Week On A Hesitant Note
February 26, 2024
Stocks are barely moving to start the week, just one session removed from record highs.
Via
Talk Markets
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
February 26, 2024
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost.
Via
Investor's Business Daily
Altimmune Stock Surges, Kerrisdale Remains Short: What You Need To Know
February 26, 2024
Altimmune shares are trading higher Monday despite a lack of company-specific news. Kerrisdale Capital told Benzinga on Monday that the firm is still short Altimmune stock.
Via
Benzinga
TEVA Stock Pops 4% as Teva Receives FDA Approval
February 26, 2024
Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar.
Via
InvestorPlace
Why Is Altimmune (ALT) Stock Up 14% Today?
February 26, 2024
Altimmune stock is rising higher on Monday as ALT investors react to positive news from rival weight loss drugmaker Zealand Pharma.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 26, 2024
Via
Benzinga
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
February 26, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
February 24, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
February 22, 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.
Via
InvestorPlace
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
February 20, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
February 20, 2024
WHY: NEW YORK, NY - (NewMediaWire) - February 20, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...
Via
TheNewswire.com
NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
February 19, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
February 14, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
February 13, 2024
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble.
Via
InvestorPlace
Altimmune Stock Sinks As Kerrisdale Capital Announces Short Position: 'Obvious Dead End'
February 13, 2024
Altimmune shares are trading lower Tuesday after short-selling investment firm Kerrisdale Capital published a new research report on the stock and announced a short position
Via
Benzinga
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 13, 2024
Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance.
Via
Benzinga
Jim Cramer Calls Affirm 'A Winner,' But Not C3.ai: 'I Can't Recommend A Stock With No Earnings'
February 13, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vertiv Holdings Co (NYSE: VRT) is "one of the great per
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
19
20
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.